Modality
Gene Therapy
MOA
ALKi
Target
PRMT5
Pathway
NF-κB
Hemophilia ACeliac
Development Pipeline
Preclinical
~May 2018
→ ~Aug 2019
Phase 1
Nov 2019
→ Oct 2028
Phase 1Current
NCT05111904
348 pts·Celiac
2019-11→2028-10·Recruiting
348 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-012.5y awayPh2 Data· Celiac
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Recruit…
Catalysts
Ph2 Data
2028-10-01 · 2.5y away
Celiac
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05111904 | Phase 1/2 | Celiac | Recruiting | 348 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 |